The Scripps Research Institute

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Pennsylvania

Other

University of Florida Research Foundation Inc

Novartis Ag

University of South Florida

University of Virginia Patent Foundation

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Nbe-therapeutics Ag

Fred Hutchinson Cancer Center

Modulation Therapeutics

Christoph Rader

Carlos F Barbas, Iii

Donald L Siegel

Vijay Bhoj

Xiuling Li

Haiyong Peng

Richard A Lerner

Lloyd J Old

Gerd J Ritter

Michael C Milone

Mark L McLaughlin

Ulf Grawunder

Sydney Welt

Roger Renzo Beerli

Ronald P Taylor

Margaret A Lindorfer

Sivasubramanian Baskar

Adrian U Wiestner

Lori Hazlehurst

Lorenz Waldmeier

Benjamin List

Doron Shabat

Berengere Vire

Rebecca Goydel

Martin W Skarzynski

William R Roush

Stanley R Riddell

Thomas U Hofer

Terrence R Burke, Jr

Carlos F Barbas

Michael Hudecek

Ka Yin Kwong

Subhash C Sinha

Dobeen Hwang

Jiahui Yang

Napon Nilchan

Joshua Thomas

Michael R Bishop

Ivan Samija

Alex Nanna

Jessica M Suschak

Alex R Nanna

Bérengère Vire

Carlos F Iii Barbas

The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.

Antibody compounds with reactive arginine and related antibody drug conjugates

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein α-receptor 4 (GFRα4).

Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).

Treatment of cancer using GFR alpha-4 chimeric antigen receptor

The invention provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.

ROR2 antibody compositions and related methods

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein &#x3b1;-receptor 4 (GFR&#x3b1;4).

An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.

Antibody targeting cell surface deposited complement protein C3d and use thereof

The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.

ROR1 antibody compositions and related methods

Dual variable domain (DVD) immunoconjugates and uses thereof are provided. Aspects of the subject immunoconjugates include a DVD immunoglobulin molecule having a first and a second variable domain, and a cargo moiety (e.g., a drug moiety) that is covalently conjugated to the second variable domain via a linker. Methods of making and using the subject immunoconjugates in the prevention and/or treatment of cancer and other diseases are also provided.

Dual variable domain immunoconjugates and uses thereof

The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).

Cyclic peptide conjugates and methods of use

The disclosure provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2, Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family &#x3b1;-receptor 4 (GFR&#x3b1;4).

Treatment of cancer using GFR &#x3b1;-4 chimeric antigen receptor

The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.

Chimeric rabbit/human ROR1 antibodies

Growing community of inventors

Jupiter, FL, United States of America

Christoph Rader